The strength and breadth of an individual's antibody repertoire are important predictors of their response to influenza infection or vaccination. Although progress has been made in understanding qualitatively how repeated exposures shape the antibody mediated immune response, quantitative understanding remains limited. We developed a set of mathematical models describing short-term antibody kinetics following influenza infection or vaccination and fit them to haemagglutination inhibition (HI) titres from 5 groups of ferrets which were exposed to different combinations of trivalent inactivated influenza vaccine (TIV with or without adjuvant), A/H3N2 priming inoculation and post-vaccination A/H1N1 inoculation. We fit models with various immunological mechanisms that have been empirically observed but are yet to be included in mathematical models of antibody landscapes, including titre ceiling effects, antigenic seniority and exposure-type specific cross reactivity. Based on the parameter estimates of the best supported models, we describe a number of key immunological
Introduction

1
Natural infection with influenza stimulates a complex and multifaceted immune 2 response to neutralise and clear the infection. [1] The adaptive immune response is of 3 particular interest for seasonal epidemic and pandemic preparedness, as responses from 4 previous exposures provide some long-term protection against reinfection and disease 5 via antibody and T-cell mediated immunity. [2, 3] Focusing on the adaptive immune 6 response is also advantageous because it can (i) be induced in advance of an epidemic 7 through vaccination and (ii) be measured and compared against correlates of protection 8 to improve public health forecasting. [4] [5] [6] [7] However, influenza is an antigenically 9 variable virus and undergoes continual antigenic drift, whereby mutations in 10 immunodominant epitopes are selected by immunological pressure, allowing influenza 11 lineages to escape population herd immunity. [8] [9] [10] This results in the continual waning 12 of long-term immunity as antibodies effective against past strains fail to neutralise novel 13 variants. [11] The current strategy for combating antigenic drift is to regularly update 14 the seasonal influenza vaccine to better represent circulating strains, resulting in an 15 arms race between virus and vaccine formulation. This approach is considered 16 sub-optimal given the failure rate of matching and manufacturing the vaccine strain in 17 advance of the epidemic period. [12, 13] Consequently, there has been a recent push 18 towards a universal influenza vaccination strategy, either through new vaccines or 19 improved strength and breadth of immunity using existing technologies. [14, 15] 
20
Whilst there is some cross-reactivity and cross-protection within influenza A virus 21 subtypes and within influenza B virus lineages, humans experience numerous infections 22 over their lives. [16] [17] [18] Each successive influenza exposure, which may be vaccination or 23 infection, can strengthen the available repertoire of T and B cells which target epitopes 24 on circulating and previously encountered strains. [19, 20] In the humoral response, this 25 occurs by boosting antibodies produced by preexisting long-lived plasma cells and 26 activated memory B cells (MBCs), and through generating a novel B cell response 27 targeting unrecognised epitopes. [21] [22] [23] Given that individuals experience repeated 28 infections and vaccinations from antigenically varied influenza viruses, interpreting the 29 composition of an observed antibody response is confounded by the complex interaction 30 of an individual's preexisting immunity, or immune history, with the infecting of each of these mechanisms and their implementation is described in S1 Supporting Grey line highlights how antibody titres to a different influenza immunogen (that is less antigenically similar to the exposure immunogens than the black line) develop in parallel driven by cross-reactive antibodies. After each exposure, antibody levels undergo linear boosting on a log scale followed by an initial, short waning phase and then a slower, long-term waning phase. This example demonstrates two exposures, initially with infection (star symbol) and subsequently with vaccine (syringe symbol), where antibody dynamics are governed by a set of parameters depending on the exposure type. Note that the y-axis is on a log scale and all observations are discrete and taken as the floor value. Model parameters are described in S1 Table. Protocol.
132
We fit each of the 64 potential model variants in a Bayesian framework using we ran 3 chains each for 5000000 iterations. Where the effective sample size (ESS) was 136 < 200 or the Gelman-Rubin diagnostic (R) was < 1.1 for any estimated parameter
137
(calculated using the 'coda' R package), we ran 5 chains each for 10000000 iterations 138 and obtained upper 95% confidence intervals forR of < 1.1 for all estimated parameters 139 presented here. [58] ESS andR estimates for all parameters are provided in S5 Table. 140
We then performed a model comparison analysis using Pareto-smoothed importance 141
sampling leave-one-out cross-validation (PSIS-LOO) with the 'loo' R package. [59, 60] to the data. Parameter estimates for these two models are shown in S3 obtained for µ from both infections (Fig 5i) , suggesting that the antibody response 231 following priming infection appeared to be persistent. We inferred that antibody titres 232 fell only marginally following the initial waning phase (µ(1 − d), Fig 5ii) . The antibody 233
waning rate was not identifiable for secondary infection due to the lack of observations 234 following this exposure. We found evidence for only low levels of homologous antibody 235 boosting following both initial and secondary doses of unadjuvanted TIV (TIV 1 and
236
TIV 2) that quickly waned to near undetectable levels during the initial waning phase. 237
The addition of an adjuvant appeared to have no significant impact on the this assay (TIV 2 compared to TIV 2 + adjuvant, Fig 4A&B) .
246
Comparison of cross reactivity by exposure type
247
In models with type-specific cross-reactivity, we found differences in the width of cross 248 reactivity elicited by the 6 exposure types shown in viruses (Fig 6) . in addition to that provided by the vaccine itself (Fig 5i) .
285
We estimated the cross reactivity of this additional boost to be broad with a However, all of the top models with antigenic seniority but no titre-dependent boosting 316
give constrained estimates for τ away from 0 ( Fig S12) . profile of boosting for primary infection was consistent across experimental groups, and 334 similar in magnitude to secondary infection. Furthermore, we found that priming subsequent vaccination.
337
Our work has a number of limitations. We had insufficient power to quantify all of 338 the mechanisms and parameters proposed here, and therefore restricted our reported 339 results to estimates that were consistent across the best supported model variants (S1 340
Supporting Protocol). The frequency at which blood samples were taken compared to 341 the number of exposure events resulted in a relatively small amount of data given the 342 number of mechanisms being explored. In particular, sampling around the biphasic 343 waning period of the vaccinations and following the final exposure event was limited, 344 resulting in poor identifiability for some of the waning and timing parameters.
345
Experiments of a similar design with fewer exposures and more frequent sampling would 346
power the model to elucidate these waning phases further and look for differences in 347 response longevity by exposure type. within influenza subtypes as well as between vaccine types. [64, 65] with an antigenic distance of 1. Model codes on x-axis relate to the first letter of each 502 mechanism as described in the table. to the first letter of each mechanism as described in the table. was also included in the model. Model codes on x-axis relate to the first letter of each 520 mechanism as described in the table.
